Charles River Launches Innovative Biotech Incubator Program Worldwide

Charles River Laboratories International, Inc., has introduced the Charles River Incubator Program (CIP). This project is designed to support early-stage biotechnology companies in advancing the discovery, development, and manufacturing of advanced therapies.

Building on the success of the company’s established global Cell and Gene Therapy (CGT) Accelerator Program (CAP), the CIP aims to assist innovation among start-ups and emerging biotech firms. The program aims to create a strong foundation for commercial success by offering cost-effective regulatory and quality guidance, personnel training, and access to laboratory space and equipment.

Kerstin Dolph, Corporate Senior Vice President of Global Manufacturing, Charles River, commented, “The Charles River Incubator Program launch, through our Global Innovation Center of Excellence, demonstrates a continued commitment to the global biotechnology industry by offering knowledge, connectivity, and priority access to the Charles River portfolio.” 

The CIP is tailored for biotech developers still in the discovery phase, typically over 24 months from submitting an Investigational New Drug (IND) or Clinical Trial Application (CTA). Meanwhile, the CAP focuses on advanced therapy developers closer to IND or CTA submission at 18-24 months from these milestones. Developers can now apply to join the next cohort of the CIP, gaining access to the resources and expertise needed to drive their innovations forward.

Explore how Charles River is accelerating biotech breakthroughs through its new incubator program.